Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 401–500 of 1,000
Gastrointestinal pH profile in subjects with irritable bowel syndrome.
Lalezari, D. (2012) · Europe PMC (PubMed Central) · Cited by 29
Fernández, L. M. B., Man, F., & Lasa, J. S. (2023) · Digestive Diseases · doi:10.1159/000528954 · Cited by 32
Eugenio, M. D., Jun, S., Cain, K. C., Jarrett, M. E., & Heitkemper, M. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2047-1 · Cited by 31
“Drug trials for IBS have focused on motility and pain sensitivity to reduce symptom distress and enhance QOL [22-24].”
BackgroundAntibiotic Therapy for the Irritable Bowel Syndrome
Tack, J. (2011) · New England Journal of Medicine · doi:10.1056/nejme1011211 · Cited by 28
Assessment of earthworm diversity and pesticide toxicity in Eudrilus Eugeniae
Archana, J., Biruntha, M., James, A. J. P., Karmegam, N., & Ponnuchamy, K. (2020) · Environmental Chemistry and Ecotoxicology · doi:10.1016/j.enceco.2020.11.001 · Cited by 28
The gut microbiota and gut disease
Fehily, S. R., Basnayake, C., Wright, E. K., & Kamm, M. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15520 · Cited by 33
Zheng, H., Zhang, C., Zhang, J., & Duan, L. (2023) · Protein & Cell · doi:10.1093/procel/pwad020 · Cited by 31
Postinfectious Chronic Gut Dysfunction: From Bench to Bedside
Collins, S. M., Chang, C., & Mearin, F. (2012) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2012.2 · Cited by 28
The effects and mechanism of action of methane on ileal motor function
Park, Y. M., Lee, Y. J., Hussain, Z., Lee, Y. H., & Park, H. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13077 · Cited by 27
An evidence-based update on the diagnosis and management of irritable bowel syndrome
Black, C. J., & Ford, A. C. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2455586 · Cited by 27
“The efficacy of rifaximin for treating IBS has been demonstrated in two large RCTs, each recruiting almost 600 patients [112].”
2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome
Choi, Y., Youn, Y. H., Kang, S. J., Shin, J. E., Cho, Y. S., Jung, Y. S., Shin, S. Y., Huh, C. W., Lee, Y. J., Koo, H. S., et al. (2025) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm25007 · Cited by 33
“185,186 A recent systematic review and network meta-analysis of pharmacological therapies in patients with IBS-D or IBS-M evaluated rifaximin, and the 2 major RCTs of rifaximin were included (rifaximin n = 624, placebo n = 634).”
Hu, Y., Ren, J., Zhan, M., Li, W., & Dai, H. (2012) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.2012.00650.x · Cited by 27
Gut microbiota and irritable bowel syndrome
Zhao, Y., & Zou, D. (2023) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13204 · Cited by 33
Vignera, S. L., Vicari, E. S. D., Castiglione, R., Condorelli, R. A., Vicari, L. O., & Calogero, A. E. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.131064 · Cited by 26
Bae, S.-H., Lee, K. J., Kim, Y., & Kim, K.-N. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.6.757 · Cited by 27
“The major treatment for IBS includes life style modification and symptomatic control, but many studies have demonstrated that rifaximin improved patients’ abdominal symptoms in nonconstipated IBS with a SIBO origin (2, 5, 6).”
BackgroundParkinson’s Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects
Ramprasad, C., Douglas, J. Y., & Moshiree, B. (2018) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-018-0201-3 · Cited by 30
Bugs on the brain; brain in the gut—seeking explanations for common gastrointestinal symptoms
Quigley, E. M. M. (2012) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-012-0865-y · Cited by 27
“Thus, the poorly absorbed antibiotic rifaximin has been shown to alleviate symptoms in diarrhoea-predominant IBS [26] and some probiotics and Bifidobacterium infantis 35624, in particular [27], have been shown to exert substantial clinical responses.”
BackgroundRifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
Boltin, D., Perets, T. T., Shporn, E., Aizic, S., Levy, S., Niv, Y., & Dickman, R. M. (2014) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-014-0049-x · Cited by 26
Clinical pilot study: efficacy of triple antibiotic therapy in
Nagel, R., Bielefeldt‐Ohmann, H., & Traub, R. J. (2014) · Gut Pathogens · doi:10.1186/s13099-014-0034-0 · Cited by 29
Dale, H. F., & Lied, G. A. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2002-57 · Cited by 32
“Three multicenter RCTs, named TARGET 1-3, have demonstrated a beneficial effect of rifaximin in improving IBS symptoms [59,60].”
BackgroundLacy, B. E., Chang, L., Rao, S. S. C., Heimanson, Z., & Sayuk, G. S. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.01.010 · Cited by 32
Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome
Cash, B. D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.908278 · Cited by 31
Recent advances in pharmacological treatment of irritable bowel syndrome.
Lazaraki, G., Chatzimavroudis, G., & Katsinelos, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8867 · Cited by 36
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation
Ponziani, F. R., Pecere, S., Lopetuso, L. R., Scaldaferri, F., Cammarota, G., & Gasbarrini, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1186639 · Cited by 25
“[52] Phase II and III trials and the registrative study have drawn a more detailed picture of safety and tolerability of rifaximin.[47,49,70] In both treatment phases and during the post-treatment follow-up, the incidence of AEs was similar to placebo and involved 52.”
BackgroundMethodTaxonomy and Biodiversity of the Genus Chaetomium in Different Habitats
Abdel-Azeem, A. M. (2019) · Fungal biology · doi:10.1007/978-3-030-31612-9_1 · Cited by 25
Personalisation of therapy in irritable bowel syndrome: a hypothesis
Black, C. J., & Ford, A. C. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00245-0 · Cited by 30
Consenso mexicano sobre el síndrome de intestino irritable
Carmona-Sánchez, R., Icaza-Chávez, M. E., Bielsa-Fernández, M. V., Gomez-Escudero, O., Bosques‐Padilla, F., Coss‐Adame, E., Esquivel-Ayanegui, F., Flores-Rendón, Á. R., González-Martínez, M. A., Huerta-Iga, F. M., et al. (2016) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2016.01.004 · Cited by 36
Treatment of irritable bowel syndrome
Basnayake, C. (2018) · Australian Prescriber · doi:10.18773/austprescr.2018.044 · Cited by 30
Bile acid–gut microbiota crosstalk in irritable bowel syndrome
Gu, Y., Li, L., Yang, M., Liu, T., Song, X., Qin, X., Xu, X. J., Liu, J., Wang, B., & Cao, H. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2058353 · Cited by 29
Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome
Barboza, J., Talley, N. J., & Moshiree, B. (2014) · Drugs · doi:10.1007/s40265-014-0292-7 · Cited by 24
“Two landmark trials—TARGET 1 and TARGET 2— showed the benefit of rifaximin in IBS-D [83].”
BackgroundIrritable Bowel Syndrome: News from an Old Disorder
Ferreira, A. I., Garrido, M., & Castro-Poças, F. (2019) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000503757 · Cited by 37
Clinical Management of the Microbiome in Irritable Bowel Syndrome
Andrews, C. N., Sidani, S., & Marshall, J. K. (2020) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwz037 · Cited by 26
“Rifaximin is a nonsystemic antibiotic that has been shown in multiple clinical trials to be effective in improving global IBS symptoms, bloating, abdominal pain and stool consistency (104,105).”
BackgroundGiacosa, A., Riva, A., Petrangolini, G., Allegrini, P., Fazia, T., Bernardinelli, L., Peroni, G., & Rondanelli, M. (2022) · Nutrients · doi:10.3390/nu14030416 · Cited by 24
Novoa-Farías, O., Frati-Munari, A. C., Peredo, M. A., Flores-Juárez, S., Novoa-García, O., Galicia-Tapia, J., & Romero-Carpio, C. E. (2015) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2015.07.003 · Cited by 23
Review article: Diagnosis and investigation of irritable bowel syndrome
Black, C. J. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16597 · Cited by 32
Serra, J. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14333 · Cited by 23
Hamd, M. A. E., Albalawi, M. A., Gomaa, H., Mohammad, B., Abdel-Kareem, R. F., Obaydo, R. H., Alsaggaf, W. T., Saleh, S. F., Alossaimi, M. A., & Abdel-Lateef, M. A.-K. (2023) · Chemosensors · doi:10.3390/chemosensors11050275 · Cited by 24
Treatment of Irritable Bowel Syndrome: Sex and Gender Specific Aspects
Voß, U., Lewerenz, A., & Nieber, K. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_21 · Cited by 25
Bugs, Stool, and the Irritable Bowel Syndrome: Too Much Is as Bad as Too Little?
Talley, N. J., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.019 · Cited by 24
Adverse events appear to unblind clinical trials in irritable bowel syndrome
Shah, E., Triantafyllou, K., Hana, A. A., & Pimentel, M. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12289 · Cited by 23
Self-citationAn approach to the care of patients with irritable bowel syndrome
Farmer, A. D., Wood, E., & Ruffle, J. K. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.190716 · Cited by 35
Does stress induce bowel dysfunction?
Chang, Y.-M., Zaatari, M. E., & Kao, J. Y. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.911659 · Cited by 25
“Furthermore, patients with IBS also have altered gut microbiota [27], and treatment of IBS patients with rifaximin led to improvement in patient symptoms [28].”
BackgroundIrritable bowel syndrome; update on pathophysiology and management
Quigley, E. M. M., & Craig, O. F. (2012) · The Turkish Journal of Gastroenterology · doi:10.4318/tjg.2012.0551 · Cited by 24
Novel pharmacological therapies for irritable bowel syndrome
Corsetti, M., & Whorwell, P. J. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1158099 · Cited by 28
“Adverse events were no different between rifaximin- and placebo-treated patients and no cases of Clostridium difficile infection or ischemic colitis were reported [53].”
BackgroundResultThe Pathology of Methanogenic Archaea in Human Gastrointestinal Tract Disease
Ishaq, S. L., Moses, P. L., & Wright, A. G. (2016) · InTech eBooks · doi:10.5772/64637 · Cited by 25
Morales, W., Τriantafyllou, Κ., Parodi, G., Weitsman, S. R., Park, S. C., Rezaie, A. R., Pichetshote, N., Lin, E. A., & Pimentel, M. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13875 · Cited by 23
Self-citationEditorial: Linaclotide: Promising IBS-C Efficacy in an Era of Provisional Study Endpoints
Sayuk, G. S. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.325 · Cited by 22
Tryptophan metabolism and the gut-brain axis: focus on specific gut microbial genera
Xia, Y., Zhang, C., Yu, L., Zhang, Q., Narbad, A., Chen, W., Zhai, Q., & Tian, F. (2025) · Journal of Future Foods · doi:10.1016/j.jfutfo.2024.09.006 · Cited by 25
Gut microbiota signatures and modulation in irritable bowel syndrome
Marasco, G., Cremon, C., Barbaro, M. R., Stanghellini, V., & Barbara, G. (2022) · Microbiome Research Reports · doi:10.20517/mrr.2021.12 · Cited by 31
A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers
Moshiree, B., Heidelbaugh, J. J., & Sayuk, G. S. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02224-z · Cited by 34
Ke, W., Wang, Y., Huang, S., Liu, S., Zhu, H., Xie, X., Yang, H., Lu, Q., Gan, J., He, G., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12312 · Cited by 24
Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies
Sopeña, F., & Lanas, Á. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11412820 · Cited by 21
“difficile-associated diarrhea or ischemic colitis and no deaths were reported [Pimentel et al. 2011] (Table 1).”
BackgroundBacterial Flora as a Cause or Treatment of Chronic Diarrhea
Scaldaferri, F., Pizzoferrato, M., Pecere, S., Forte, F., & Gasbarrini, A. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.06.002 · Cited by 25
Intestinal Microbiota: Its Role in Digestive Diseases
Fernández, L. M. B., Lasa, J. S., & Man, F. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000153 · Cited by 26
Cash, B. D., Lacy, B. E., Rao, T., & Earnest, D. L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118052 · Cited by 22
“rifaximin treatment in non-constipation IBS patients (non C-IBS), and (2) the TARGET 3 trial that assessed the safety and efficacy of repeat treatment with rifaximin in IBS-D patients who initially responded to rifaximin treatment but had subsequent recurrence of symptoms.[21,29] TARGET 1 and TARGET 2 were iden-”
BackgroundMethodResultInfluentialClose association between intestinal microbiota and irritable bowel syndrome
Fan, W.-T., Ding, C., Xu, N., Zong, S., Ma, P., & Gu, B. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3060-2 · Cited by 25
Delivery of care for functional gastrointestinal disorders: A systematic review
Basnayake, C., Kamm, M. A., Salzberg, M. R., Wilson-O'Brien, A. L., Stanley, A., & Thompson, A. J. V. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14830 · Cited by 23
da Silva, B. C., Ramos, G. P., Barros, L. L., RAMOS, A. F. P., Domingues, G. R. D. S., Chinzon, D., & Passos, M. D. C. F. (2025) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612024-107 · Cited by 30
“The incidence of adverse events was similar in both groups (57) .”
Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
Schey, R., Iorio, N., & Malik, Z. A. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s67231 · Cited by 24
Irritable Bowel Syndrome in Pregnancy
Moosavi, S., Pimentel, M., Wong, M. S., & Rezaie, A. R. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001124 · Cited by 22
Self-citationMetabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission
Shute, A., Bihan, D. G., Lewis, I. A., & Nasser, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.917197 · Cited by 23
“The non-absorbable antibiotic rifaximin is approved for the treatment of diarrhea-predominant IBS patients and has modest effects on IBS symptom severity (Pimentel et al., 2011; Lembo et al., 2016).”
BackgroundGargari, G., Mantegazza, G., Taverniti, V., Gardana, C., Valenza, A., Rossignoli, F., Barbaro, M. R., Marasco, G., Cremon, C., Barbara, G., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2274128 · Cited by 25
Managing Irritable Bowel Syndrome
Anastasi, J. K., Capili, B., & Chang, M. (2013) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000431911.65473.35 · Cited by 26
“The most common adverse events associated with rifaximin are headache, upper respiratory infection, abdominal pain, nausea, and diarrhea.(62) Long-term safety, efficacy over repeated treatment courses, and the potential for antibiotic resistance require further investigation.”
BackgroundNardo, G. D., Oliva, S., Ferrari, F., Mallardo, S., Barbara, G., Cremon, C., Aloi, M., & Cucchiara, S. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-142 · Cited by 20
“Recently, the use of antibiotics seems to provide significant relief of functional GI symptoms, bloating and abdominal pain, but the need for repeated treatment cycles may have an important impact on the intestinal bacterial flora [21,22], especially in children.”
BackgroundMisch, C. M. (2010) · PubMed · Cited by 20
Papale, A. J., Flattau, R., Vithlani, N., Mahajan, D., & Nadella, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226948 · Cited by 28
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
“It has FDA approval for treating irritable bowel syndrome (IBS) [269–272], hepatic encephalopathy for reducing recurrent episodes [273–276], and traveler’s diarrhea [277–280].”
Overgrowth of the indigenous gut microbiome and irritable bowel syndrome
Bye, W. A., Ishaq, N., Bolin, T. D., Duncombe, V. M., & Riordan, S. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2449 · Cited by 21
Liu, R., & Staller, K. D. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s216056 · Cited by 19
Chuah, K. H., Hian, W. X., Lim, S. Z., Beh, K. H., & Mahadeva, S. (2023) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13189 · Cited by 25
“Although rifaximin was reported to be effective in treating nonconstipated IBS in a randomized controlled trial, but the absolute reduction compared to placebo was only 10%.(23) Meanwhile, an open-label rifaximin trial involving subjects with IBS-D demonstrated that the optimal benefit of rifaximin was seen in those w…”
BackgroundMozaffari, S., Nikfar, S., & Abdollahi, M. R. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759558 · Cited by 21
“/ PO/10 d/10 wks/P 87 IBS patients/Rome I/NA R, DB, PC # Abd bloating and improve IBS symptoms [16] Rifaximin/550 mg/t.”
BackgroundCurrent and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome
Nee, J. W., Zakari, M., & Lembo, A. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1101449 · Cited by 22
“[71,72] Rifaximin is a minimally absorbed antibiotic that covers both gram positives and negatives.”
BackgroundSelf-citationIs irritable bowel syndrome an infectious disease?
Thompson, J. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i4.1331 · Cited by 21
Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective
Giron, F., & Quigley, E. M. M. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18004 · Cited by 20
“64 The original hypothesis, namely the elimination of SIBO, is unlikely to explain most of the effect as the true prevalence of SIBO in IBS is probably low,65,66 none of the pivotal studies reported on its presence or contribution to the benefits of rifaximin61-63 and other studies have indicated that this antibiotic…”
BackgroundResultInfluentialShah, E. D., Saini, S. D., & Chey, W. D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.02.039 · Cited by 19
Self-citationUpdate on Pharmacotherapy for Irritable Bowel Syndrome
Munjal, A., Dedania, B. K., & Cash, B. D. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0692-7 · Cited by 22
The Future of Probiotics for Disorders of the Brain-Gut Axis
Quigley, E. M. M., & Shanahan, F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_19 · Cited by 20
Rifaximin for the treatment of irritable bowel syndrome
Cremonini, F., & Lembo, A. J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.651458 · Cited by 19
“Following the results of the Phase II studies, two identical large Phase III randomized placebo controlled trials (TARGET 1 and TARGET 2) were performed in the US and Canada [37].”
Self-citationPrevalence, risk factors, and treatment of small intestinal bacterial overgrowth in children
Cho, Y. K., Lee, J. Y., & Paik, C. N. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.00969 · Cited by 18
Microbiota modulation in disorders of gut-brain interaction
Marasco, G., Cremon, C., Barbaro, M. R., Bianco, F., Stanghellini, V., & Barbara, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.004 · Cited by 23
Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options
Pastras, P., Aggeletopoulou, I., & Triantos, C. K. (2024) · Microorganisms · doi:10.3390/microorganisms12102036 · Cited by 20
“Antibiotic use may also play a role in altering the microbiota and influencing IBS symptoms [95,96].”
BackgroundColonic diverticular disease. Treatment and prevention
Gargallo-Puyuelo, C. J., Sopeña, F., & Arbeloa, Á. L. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.03.010 · Cited by 18
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
Laterza, L., Ianiro, G., Scoleri, I., Landi, R., Bruno, G., Scaldaferri, F., Gaetani, E., Campanale, M., & Gasbarrini, A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1007951 · Cited by 21
“Chemical structure C43H51N3O11 Pivotal trial(s) [31] L.”
BackgroundInfluentialThe Mexican consensus on irritable bowel syndrome
Carmona-Sánchez, R., Icaza-Chávez, M. E., Bielsa-Fernández, M. V., Gomez-Escudero, O., Bosques‐Padilla, F., Coss‐Adame, E., Esquivel-Ayanegui, F., Flores-Rendón, Á. R., González-Martínez, M. A., Huerta-Iga, F. M., et al. (2016) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2016.01.004 · Cited by 25
Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome
Emmanuel, A. V., Landis, D. L., Peucker, M., & Hungin, A. P. S. (2016) · Frontline Gastroenterology · doi:10.1136/flgastro-2015-100651 · Cited by 18
Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
Fragkos, K. C. (2017) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s123621 · Cited by 22
“It is an oral, non-absorbable, broad-spectrum antibiotic targeting gut flora and has been shown to relieve IBS symptoms, bloating, abdominal pain, and loose or watery stools better than the placebo for up to 10 weeks after completion of therapy with repeat courses not hindering its durability.(51) Alosetron and ondans…”
BackgroundInfluence of Dietary Restriction on Irritable Bowel Syndrome
Kamal, A., & Pimentel, M. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0241-2 · Cited by 20
Self-citationProbiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold
Compare, D., Sgamato, C., Nardone, O. M., Rocco, A., Coccoli, P., Laurenza, C., & Nardone, G. (2021) · Digestive Diseases · doi:10.1159/000516023 · Cited by 25
ARMA-based spectral bandwidth for evaluation of bowel motility by the analysis of bowel sounds
Emoto, T., Shono, K., Abeyratne, U. R., Okahisa, T., Yano, H., Akutagawa, M., Konaka, S., & Kinouchi, Y. (2013) · Physiological Measurement · doi:10.1088/0967-3334/34/8/925 · Cited by 18
“IBS is characterized by continuous or recurrent symptoms of abdominal pain and abdominal bowel habits that are associated with altered motility of the intestine (Pimentel et al 2011, Craine et al 1999).”
BackgroundBruzzese, E., Pesce, M., Sarnelli, G., & Guarino, A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1488964 · Cited by 22
Irritable bowel syndrome – Diarrhoea
Wald, A. M. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.11.002 · Cited by 21
Stuijver, D. J. F., Romualdi, E., van Zaane, B., Bax, L., Buller, H. R., Gerdes, V. E. A., & Squizzato, A. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1168-2 · Cited by 19
Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?
Purssell, H., Whorwell, P. J., Athwal, V. S., & Vasant, D. H. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.1816 · Cited by 24
Belgian consensus on irritable bowel syndrome
Kindt, S., Louis, H., Schepper, H. U. D., Arts, J., Caenepeel, P., Looze, D. A. D., Gerkens, A., Holvoet, T., Latour, P., Mahler, T., et al. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.10100 · Cited by 26
Changing Trends in Mental Health Care and Research in Ghana
Ofori-Atta, A. L., & Ohene, S. (2014) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · Cited by 22
Shin, A., Xing, Y., Waseem, M. R., Siwiec, R. M., James-Stevenson, T. N., Rogers, N. A., Bohm, M. E., Wo, J. M., Lockett, C. J., Gupta, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19363-2 · Cited by 30
“Our findings may further explain the higher prevalence of mixed-and diarrhea-predominant symptoms in post-infection IBS 43,44 as well as the limited evidence for efficacy of antimicrobial treatments such as rifaximin in IBS-C 45 relative to IBS-D 46,47 .”
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
Sobolewska-Włodarczyk, A., Włodarczyk, M., Storr, M., & Fichna, J. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s83722 · Cited by 18
“The potential of rifaximin in IBS treatment was observed in two identically designed, double-blind, placebocontrolled trials (TARGET 1 and TARGET 2).(14) In these studies, 1,260 patients with IBS without constipation were randomized to receive either rifaximin 550 mg or placebo, three times daily for 2 weeks, and were…”
InfluentialChang, C. (2018) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s167031 · Cited by 20
“5%) being the most commonly reported AEs.(52) In addition, no patients reported C.”
InfluentialGuo, H., Lu, S., Zhang, J., Chen, C., Du, Y., Wang, K., & Duan, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1121435 · Cited by 23
“The key secondary outcome we designed was similar to the relief of IBS global symptoms (Pimentel et al., 2011).”
The safety of novel drugs used to treat irritable bowel syndrome
Mozaffari, S., Nikfar, S., & Abdollahi, M. R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.902932 · Cited by 16
“The most common adverse events in rifaximin-treated groups were headache, upper respiratory infection, nausea, nasopharyngitis, diarrhea and abdominal pain [56-58].”
BackgroundInfluential
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.